THE WIRE · № 63329
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
01 THE MACHINE READ
WHY IT MATTERS.
First-in-human proof that saRNA can upregulate a target protein supports a new RNA-activation drug class for genetic disease.
RNA activation shows early human mechanism proof
Larger trials and regulatory feedback
Single small study; utrophin gains may not translate clinically
FULL DISPATCH
First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-02 16:22 UTC
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL2026-10-02 19:05 UTC
XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies2026-10-02 22:33 UTC
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)2026-10-02 22:42 UTC
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 20262026-10-03 00:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.